LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Novo Nordisk A-S

Uždarymo kaina

SektoriusSveikatos priežiūra

67.74 0.61

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

67.19

Max

68.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

804M

29B

Pardavimai

-7.6B

78B

P/E

Sektoriaus vid.

19.207

50.291

Pelnas, tenkantis vienai akcijai

6.53

Dividendų pajamingumas

2.32

Pelno marža

37.182

Darbuotojai

77,406

EBITDA

5.9B

46B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+40.74% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.32%

2.40%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

43B

309B

Ankstesnė atidarymo kaina

67.13

Ankstesnė uždarymo kaina

67.74

Naujienos nuotaikos

By Acuity

80%

20%

359 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Novo Nordisk A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-16 11:36; UTC

Svarbiausios naujienos

Novo Nordisk CEO to Step Down Amid Market Challenges

2025-05-12 09:36; UTC

Pagrindinės rinkos jėgos

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

2025-05-07 11:29; UTC

Svarbiausios naujienos
Uždarbis
Pagrindinės rinkos jėgos

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

2025-06-24 10:26; UTC

Rinkos pokalbiai

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

2025-06-23 13:09; UTC

Rinkos pokalbiai

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

2025-06-20 13:31; UTC

Įsigijimai, susijungimai, perėmimai

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

2025-06-13 11:39; UTC

Rinkos pokalbiai

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

2025-06-13 10:04; UTC

Rinkos pokalbiai

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

2025-06-11 09:45; UTC

Rinkos pokalbiai

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

2025-06-10 13:38; UTC

Karštos akcijos

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

2025-06-09 10:09; UTC

Rinkos pokalbiai

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

2025-06-03 15:03; UTC

Įsigijimai, susijungimai, perėmimai

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

2025-05-29 01:00; UTC

Svarbiausios naujienos

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

2025-05-20 14:08; UTC

Uždarbis

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

2025-05-20 07:43; UTC

Rinkos pokalbiai

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

2025-05-16 18:35; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

2025-05-16 17:34; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

2025-05-16 13:42; UTC

Karštos akcijos

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

2025-05-16 13:27; UTC

Rinkos pokalbiai

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

2025-05-16 13:15; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

2025-05-16 12:17; UTC

Uždarbis

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

2025-05-12 22:14; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025-05-12 18:45; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025-05-12 12:07; UTC

Rinkos pokalbiai

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

2025-05-12 07:20; UTC

Rinkos pokalbiai

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

2025-05-07 15:13; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

2025-05-07 13:56; UTC

Uždarbis

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

2025-05-07 13:45; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

2025-05-07 11:25; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

2025-05-07 11:18; UTC

Uždarbis

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Novo Nordisk A-S Prognozė

Kainos tikslas

By TipRanks

40.74% į viršų

12 mėnesių prognozė

Vidutinis 94.79 USD  40.74%

Aukščiausias 142.564 USD

Žemiausias 61 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novo Nordisk A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

4

Pirkti

3

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

62.63 / 69.23Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

359 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.